D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 80 Citations 20,599 311 World Ranking 12007 National Ranking 608

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Cancer
  • Internal medicine

The scientist’s investigation covers issues in Internal medicine, Breast cancer, Cancer research, Urokinase and Plasminogen activator. His Internal medicine research includes elements of Endocrinology and Oncology. Breast cancer is the subject of his research, which falls under Cancer.

His biological study spans a wide range of topics, including Cell, Gene expression and Plasmin. His studies deal with areas such as Survival rate, Primary tumor and Immunology as well as Urokinase. He has researched Plasminogen activator in several fields, including Proteases, Node negative and Antigen.

His most cited work include:

  • Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. (517 citations)
  • BCR-ABL Maintains Resistance of Chronic Myelogenous Leukemia Cells to Apoptotic Cell Death (435 citations)
  • BCR-ABL Maintains Resistance of Chronic Myelogenous Leukemia Cells to Apoptotic Cell Death (435 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of study are Internal medicine, Breast cancer, Cancer research, Plasminogen activator and Oncology. His work on Endocrinology expands to the thematically related Internal medicine. The various areas that he examines in his Breast cancer study include Immunology, Chemotherapy and Pathology.

Manfred Schmitt interconnects Cancer cell, Tumor progression, Cell and In vivo in the investigation of issues within Cancer research. The concepts of his Plasminogen activator study are interwoven with issues in Proteases, Plasmin and Urokinase. Manfred Schmitt works mostly in the field of Oncology, limiting it down to concerns involving DNA methylation and, occasionally, Methylation.

He most often published in these fields:

  • Internal medicine (36.32%)
  • Breast cancer (34.27%)
  • Cancer research (29.92%)

What were the highlights of his more recent work (between 2012-2021)?

  • Breast cancer (34.27%)
  • Cancer research (29.92%)
  • Oncology (27.37%)

In recent papers he was focusing on the following fields of study:

Manfred Schmitt mainly investigates Breast cancer, Cancer research, Oncology, Internal medicine and Pathology. His Breast cancer study is related to the wider topic of Cancer. His Cancer research research is multidisciplinary, incorporating perspectives in Cancer cell, Immunology, Urokinase receptor, Ovarian cancer and Triple-negative breast cancer.

His study in Oncology is interdisciplinary in nature, drawing from both Hazard ratio, Anthracycline, Lymph node, Endocrine system and Biomarker. His biological study focuses on Cohort. His Pathology study also includes

  • Lower risk which connect with Gene rearrangement,
  • Surgical oncology which is related to area like Multiplex ligation-dependent probe amplification, Prospective cohort study, Plasminogen activator inhibitor-1 and Metastatic breast cancer.

Between 2012 and 2021, his most popular works were:

  • uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. (143 citations)
  • Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients (107 citations)
  • CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer (100 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Cancer
  • Enzyme

Cancer research, Breast cancer, Pathology, Metastasis and Cancer are his primary areas of study. His Cancer research research integrates issues from CXCL10, CXCL9, Cancer cell, Ovarian cancer and microRNA. The Breast cancer study combines topics in areas such as HEK 293 cells, Tumor progression, Proteomics and Cell growth.

His Metastasis research is classified as research in Internal medicine. His Clinical Oncology, Node negative and Plasminogen activator study, which is part of a larger body of work in Internal medicine, is frequently linked to Risk assessment, bridging the gap between disciplines. His Cancer study combines topics in areas such as Lung and Human genetics.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.

Maxime P. Look;Wim L. J. van Putten;Michael J. Duffy;Nadia Harbeck.
Journal of the National Cancer Institute (2002)

753 Citations

BCR-ABL Maintains Resistance of Chronic Myelogenous Leukemia Cells to Apoptotic Cell Death

Anne McGahon;Reid Bissonnette;Reid Bissonnette;Manfred Schmitt;Manfred Schmitt;Kate M. Cotter;Kate M. Cotter.
Blood (1994)

691 Citations

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

F. Janicke;A. Prechtl;C. Thomssen;N. Harbeck.
Journal of the National Cancer Institute (2001)

605 Citations

Increased Neutrophil-Platelet Adhesion in Patients With Unstable Angina

I Ott;F J Neumann;M Gawaz;M Schmitt.
Circulation (1996)

565 Citations

The Urokinase System of Plasminogen Activation and Prognosis in 2780 Breast Cancer Patients

J. A. Foekens;H. A. Peters;M. P. Look;H. Portengen.
Cancer Research (2000)

561 Citations

Clinical impact of the plasminogen activation system in tumor invasion and metastasis : Prognostic relevance and target for therapy

M Schmitt;N Harbeck;C Thomssen;O Wilhelm.
Thrombosis and Haemostasis (1997)

560 Citations

Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer

Fritz Jänicke;Manfred Schmitt;Lothar Pache;Kurt Ulm.
Breast Cancer Research and Treatment (1993)

492 Citations

Increased Expression of Matrix Metalloproteinases (MMP)-2, MMP-9, and the Urokinase-Type Plasminogen Activator Is Associated with Progression from Benign to Advanced Ovarian Cancer

Barbara Schmalfeldt;Dieter Prechtel;Kathrin Härting;Kerstin Späthe.
Clinical Cancer Research (2001)

489 Citations

Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b.

A Schnelzer;D Prechtel;U Knaus;K Dehne.
Oncogene (2000)

473 Citations

Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA).

H Kobayashi;M Schmitt;L Goretzki;N Chucholowski.
Journal of Biological Chemistry (1991)

469 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Manfred Schmitt

Eleftherios P. Diamandis

Eleftherios P. Diamandis

Mount Sinai Hospital

Publications: 154

Nils Brünner

Nils Brünner

University of Copenhagen

Publications: 70

Viktor Magdolen

Viktor Magdolen

Technical University of Munich

Publications: 59

Andreas Scorilas

Andreas Scorilas

National and Kapodistrian University of Athens

Publications: 59

Michael J. Duffy

Michael J. Duffy

University College Dublin

Publications: 47

Judith A. Clements

Judith A. Clements

Queensland University of Technology

Publications: 45

Hiroshi Kobayashi

Hiroshi Kobayashi

Nara Medical University

Publications: 42

John A. Foekens

John A. Foekens

Erasmus University Rotterdam

Publications: 41

Keld Danø

Keld Danø

Copenhagen University Hospital

Publications: 41

Bonnie F. Sloane

Bonnie F. Sloane

Wayne State University

Publications: 40

George M. Yousef

George M. Yousef

University of Toronto

Publications: 35

Michael Ploug

Michael Ploug

University of Copenhagen

Publications: 34

Algirdas J. Jesaitis

Algirdas J. Jesaitis

Montana State University

Publications: 33

Peter A. Andreasen

Peter A. Andreasen

Aarhus University

Publications: 31

Ib Jarle Christensen

Ib Jarle Christensen

University of Copenhagen

Publications: 29

Mingdong Huang

Mingdong Huang

Fuzhou University

Publications: 29

Trending Scientists

David Marshall

David Marshall

Cardiff University

Pasquale Foggia

Pasquale Foggia

University of Salerno

John Goddard

John Goddard

Bangor University

James N. Guichard

James N. Guichard

Futurewei Technologies

Pei Zhong

Pei Zhong

Duke University

Yuriko Renardy

Yuriko Renardy

Virginia Tech

Johannes Gierschner

Johannes Gierschner

IMDEA Nanoscience

Kenzo Hiraoka

Kenzo Hiraoka

University of Yamanashi

Duncan J. Irschick

Duncan J. Irschick

University of Massachusetts Amherst

Jean Djiane

Jean Djiane

INRAE : Institut national de recherche pour l'agriculture, l'alimentation et l'environnement

Jianghong Meng

Jianghong Meng

University of Maryland, College Park

Haruo Sato

Haruo Sato

Tohoku University

Tamara S. Galloway

Tamara S. Galloway

University of Exeter

Havala O. T. Pye

Havala O. T. Pye

Environmental Protection Agency

Harold Pashler

Harold Pashler

University of California, San Diego

William J. Jusko

William J. Jusko

University at Buffalo, State University of New York

Something went wrong. Please try again later.